ChemoCentryx, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514400611 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.40M $85.30M $124.5M
YoY Change -44.94% -31.49% -0.8%
Cash & Equivalents $16.08M $20.90M $22.32M
Short-Term Investments $57.30M $64.40M $102.2M
Other Short-Term Assets $1.000M $800.0K $600.0K
YoY Change 66.67% 33.33% -25.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $74.33M $86.07M $125.6M
YoY Change -44.66% -31.49% -0.69%
LONG-TERM ASSETS
Property, Plant & Equipment $1.208M $1.193M $1.440M
YoY Change -13.65% -17.15% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $41.30M $39.40M $32.70M
YoY Change 148.8% 20.49% 1067.86%
Other Assets $181.0K $200.0K $160.0K
YoY Change 13.13% 25.0% -20.0%
Total Long-Term Assets $42.65M $40.76M $34.33M
YoY Change 135.39% 18.72% 737.34%
TOTAL ASSETS
Total Short-Term Assets $74.33M $86.07M $125.6M
Total Long-Term Assets $42.65M $40.76M $34.33M
Total Assets $117.0M $126.8M $160.0M
YoY Change -23.25% -20.71% 22.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $748.0K $1.030M $692.0K
YoY Change -17.71% 48.84% 15.33%
Accrued Expenses $7.442M $7.050M $5.004M
YoY Change 31.74% 40.89% -16.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $400.0K
YoY Change -100.0% -100.0% -20.0%
Total Short-Term Liabilities $8.190M $8.127M $6.485M
YoY Change 19.18% 25.32% -44.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% -80.0%
Other Long-Term Liabilities $185.0K $189.0K $222.0K
YoY Change -18.14% -14.86% -55.6%
Total Long-Term Liabilities $185.0K $189.0K $222.0K
YoY Change -23.55% -14.86% -77.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.190M $8.127M $6.485M
Total Long-Term Liabilities $185.0K $189.0K $222.0K
Total Liabilities $8.375M $8.316M $6.769M
YoY Change 17.73% 22.85% -46.28%
SHAREHOLDERS EQUITY
Retained Earnings -$219.8M -$207.6M -$163.3M
YoY Change 27.15% 27.11%
Common Stock $328.5M $43.00K $43.00K
YoY Change 763813.95% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.6M $118.5M $153.2M
YoY Change
Total Liabilities & Shareholders Equity $117.0M $126.8M $160.0M
YoY Change -23.25% -20.71% 22.48%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43340506 shares
CY2012Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.00
CY2012Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
150000 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22315000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43335756 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43335756 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1700000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Investment
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1700399 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7177118 shares
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8127000
CY2014Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1030000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-207601000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7050000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
118507000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
189000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
469000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126823000
CY2014Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
326095000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
516000
CY2014Q3 us-gaap Liabilities
Liabilities
8316000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1613000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2014Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
47000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20896000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16600000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1193000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1263953
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
122438000
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
122453000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122438000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
767000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44000
CY2014Q3 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2014Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18671000
CY2014Q3 us-gaap Long Term Investments
LongTermInvestments
39364000
CY2014Q3 us-gaap Assets
Assets
126823000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
64403000
CY2014Q3 us-gaap Cash
Cash
2200000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
86066000
CY2014Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2014Q3 ccxi Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments
0
CY2014Q3 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2014Q3 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
4452000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42888168 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42888168 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2383920 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5301622 shares
CY2013Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6872000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
909000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172862000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5649000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
145308000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
226000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152422000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318103000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
399000
CY2013Q4 us-gaap Liabilities
Liabilities
7114000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1589000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
66000
CY2013Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
314000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10258000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1399000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
147828000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
147788000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
147828000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
596000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
393000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8212000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
16561000
CY2013Q4 us-gaap Assets
Assets
152422000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
123055000
CY2013Q4 us-gaap Cash
Cash
2000000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
134302000
CY2013Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q4 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2013Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
3337000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26865000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40262000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5522876 shares
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
426000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-633000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
119253000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29444000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29123000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
314000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5335000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
445000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Net Income Loss
NetIncomeLoss
-29130000
us-gaap Investment Income Interest
InvestmentIncomeInterest
360000
us-gaap Interest Paid
InterestPaid
22000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3385000
us-gaap Interest Expense
InterestExpense
46000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26124000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13855000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1363000
us-gaap Depreciation
Depreciation
426000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
66836000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64365000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1243000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26116000
us-gaap Costs And Expenses
CostsAndExpenses
34779000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8655000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2585000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
93582000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
us-gaap Share Based Compensation
ShareBasedCompensation
4699000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.60
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Trading Symbol
TradingSymbol
CCXI
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
283000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-393000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Description of Business</b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemoattractant receptor-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Unaudited Interim Financial Information</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#xA0;31, 2013 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s financial statements and the notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#xA0;31, 2013 filed with the Securities and Exchange Commission on March&#xA0;14, 2014.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24380000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2470900 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2606035 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43239000 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M28D
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
222514 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.51
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7519426 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain items in the notes to Condensed Consolidated Financial Statements have been reclassified to conform to the current fiscal year&#x2019;s format.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
372890 shares
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
74349000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
171000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
40000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-54000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35109000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34793000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
208000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Net Income Loss
NetIncomeLoss
-34739000
us-gaap Investment Income Interest
InvestmentIncomeInterest
391000
us-gaap Interest Paid
InterestPaid
95000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
us-gaap Interest Expense
InterestExpense
21000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24694000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10638000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1438000
us-gaap Depreciation
Depreciation
414000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1365000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1860000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
33653000
us-gaap Costs And Expenses
CostsAndExpenses
35109000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10415000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
121000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1648000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
108210000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
us-gaap Share Based Compensation
ShareBasedCompensation
6344000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
shares
ccxi Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
shares
ccxi Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
Less than two years
ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Shares Authorized Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAuthorizedWeightedAverageExercisePrice
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
222514 shares
CY2012Q1 ccxi Warrant Contractual Term
WarrantContractualTerm
P10Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42839000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
173000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9553000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9260000
CY2014Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-10941000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
116000
CY2014Q3 us-gaap Interest Expense
InterestExpense
4000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120000
CY2013Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1522000
CY2013Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-9433000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
134000
CY2013Q3 us-gaap Interest Expense
InterestExpense
14000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8193000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
11075000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2882000
CY2013Q3 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2013Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43336000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2014Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-36000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11053000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10977000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
112000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7543000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
11053000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3510000
CY2014Q3 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2000000
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q3 ccxi Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares

Files In Submission

Name View Source Status
0001193125-14-400611-index-headers.html Edgar Link pending
0001193125-14-400611-index.html Edgar Link pending
0001193125-14-400611.txt Edgar Link pending
0001193125-14-400611-xbrl.zip Edgar Link pending
ccxi-20140930.xml Edgar Link completed
ccxi-20140930.xsd Edgar Link pending
ccxi-20140930_cal.xml Edgar Link unprocessable
ccxi-20140930_def.xml Edgar Link unprocessable
ccxi-20140930_lab.xml Edgar Link unprocessable
ccxi-20140930_pre.xml Edgar Link unprocessable
d787708d10q.htm Edgar Link pending
d787708dex311.htm Edgar Link pending
d787708dex312.htm Edgar Link pending
d787708dex321.htm Edgar Link pending
d787708dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending